XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa

World News: . []

AUSTIN Texas May 23 2019 GLOBE NEWSWIRE -- LINK  NASDAQ XBIT announced plans to LINK  its dermatology program for its true human antibody bermekimab with the LINK  of a randomized double-blind placebo controlled Phase 2b clinical study i...

More news and information about XBiotech Inc.

Published By:

Globe Newswire: 13:20 GMT Thursday 23rd May 2019

Published: .

Search for other references to "xbiotech" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us